Terms: = Ovarian cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Diagnosis
66 results:
1. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
2. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract] [Full Text] [Related]
3. Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
Cerrato C; Pandolfo SD; Autorino R; Panunzio A; Tafuri A; Porcaro AB; Veccia A; De Marco V; Cerruto MA; Antonelli A; Derweesh IH; Maresma MCM
World J Urol; 2023 Jul; 41(7):1741-1749. PubMed ID: 36964236
[TBL] [Abstract] [Full Text] [Related]
4. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
5. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a diagnosis of Epithelial Tubo-ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract] [Full Text] [Related]
6. The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.
Ye S; Zhou S; Zhong S; Shan B; Jiang W; Yang W; Cai X; Yang H
BMC Cancer; 2022 Apr; 22(1):449. PubMed ID: 35461222
[TBL] [Abstract] [Full Text] [Related]
7. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract] [Full Text] [Related]
8. Association of Pathogenic Variants in Hereditary cancer Genes With Multiple Diseases.
Zeng C; Bastarache LA; Tao R; Venner E; Hebbring S; Andujar JD; Bland ST; Crosslin DR; Pratap S; Cooley A; Pacheco JA; Christensen KD; Perez E; Zawatsky CLB; Witkowski L; Zouk H; Weng C; Leppig KA; Sleiman PMA; Hakonarson H; Williams MS; Luo Y; Jarvik GP; Green RC; Chung WK; Gharavi AG; Lennon NJ; Rehm HL; Gibbs RA; Peterson JF; Roden DM; Wiesner GL; Denny JC
JAMA Oncol; 2022 Jun; 8(6):835-844. PubMed ID: 35446370
[TBL] [Abstract] [Full Text] [Related]
9. Early age of onset and broad cancer spectrum persist in msh6- and PMS2-associated Lynch syndrome.
Liu YL; Cadoo KA; Maio A; Patel Z; Kemel Y; Salo-Mullen E; Catchings A; Ranganathan M; Kane S; Soslow R; Ceyhan-Birsoy O; Mandelker D; Carlo MI; Walsh MF; Shia J; Markowitz AJ; Offit K; Stadler ZK; Latham A
Genet Med; 2022 Jun; 24(6):1187-1195. PubMed ID: 35346574
[TBL] [Abstract] [Full Text] [Related]
10. Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma: A Clinicopathologic and Molecular Analysis of 9 Tumors Based on the TCGA Classifier.
Safdar NS; Thompson EF; Gilks CB; Isacson C; Bennett JA; Clarke B; Young RH; Oliva E
Am J Surg Pathol; 2021 Aug; 45(8):1038-1046. PubMed ID: 34115671
[TBL] [Abstract] [Full Text] [Related]
11. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
Laish I; Friedman E; Levi-Reznick G; Kedar I; Katz L; Levi Z; Halpern N; Parnasa S; Abu-Shatya A; Half E; Goldberg Y
Breast Cancer Res Treat; 2021 Aug; 188(3):685-694. PubMed ID: 34086170
[TBL] [Abstract] [Full Text] [Related]
12. Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
Ferrer-Avargues R; Castillejo MI; Dámaso E; Díez-Obrero V; Garrigos N; Molina T; Codoñer-Alejos A; Segura Á; Sánchez-Heras AB; Castillejo A; Soto JL
Cancer Commun (Lond); 2021 Mar; 41(3):218-228. PubMed ID: 33630411
[TBL] [Abstract] [Full Text] [Related]
13. Lynch syndrome-associated repeated stroke with MLH1 frame-shift mutation.
Zhang M; Yang H; Chen Z; Fan Y; Hu X; Liu W
Neurol Sci; 2021 Apr; 42(4):1631-1635. PubMed ID: 33433757
[TBL] [Abstract] [Full Text] [Related]
14. Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix.
Kang EY; Tessier-Cloutier B; Duggan MA; Stewart CJR; Lee CH; Köbel M
Histopathology; 2021 Aug; 79(2):160-167. PubMed ID: 33432679
[TBL] [Abstract] [Full Text] [Related]
15. Diffuse Intratumoral Stromal Inflammation in ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract] [Full Text] [Related]
16. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract] [Full Text] [Related]
17. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes.
Bogani G; Tibiletti MG; Ricci MT; Carnevali I; Liberale V; Paolini B; Milione M; Vitellaro M; Murgia F; Chiappa V; Ditto A; Ghezzi F; Raspagliesi F
Int J Gynecol Cancer; 2020 Jan; 30(1):56-61. PubMed ID: 31780564
[TBL] [Abstract] [Full Text] [Related]
18. The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review).
Christophersen MK; Høgdall C; Høgdall E
Int J Mol Med; 2019 Nov; 44(5):1599-1608. PubMed ID: 31573049
[TBL] [Abstract] [Full Text] [Related]
19. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
[TBL] [Abstract] [Full Text] [Related]
20. [The French Genetic and cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract] [Full Text] [Related]
[Next]
